

# TruSight Oncology 500 (TSO500) ctDNA Assay

The TruSight Oncology 500 (TSO500) ctDNA assay employs a hybrid-capture approach for target enchrichment of 523 clinically relevant genes and leverages unique molecular indices to enable ultra-low frequency detection of SNVs, Indels, and CNVs. This comprehensive cancer panel interrogates relevant cancer biomarkers with as little as 20-30 ng of cfDNA and demonstrates robust analytical performance. In addition to variant calls, the assay reports a tumor mutational burden (TMB) score and microsatellite instability (MSI) scores. Available at our genomics laboratories in Durham, NC, US and Beijing, China.

## TMB methodology


Enhanced algorithm to robustly call TMB from cfDNA. Reports include a synonymous and non-synonymous score using eligible variants that meet the following criteria:

- Variants in the coding region (RefSeq Cds)
- · Variants not in low confidence regions (black list)
- Variant Frequency ≥ Minimum reporting TMB threshold
- Coverage ≥ 1000
- SNVs and Indels (MNVs excluded)
- Nonsynonymous and synonymous variants
- Variants with cosmic count > 50 excluded
- Exclude clonal hematopoiesis driver genes
- Exclude variants with VAF > 40%

### **HIGHLIGHTS**

- Reportable biomarkers: SNVs, Indels, CNVs, MSI, and TMB
- Sample types: Streck whole blood, Streck & EDTA plasma, cfDNA
- Pre-analytical QC incudes Fragment Analysis Quantification
- Detection of variants down to 0.5% VAF
- Sensitivity of SNVs at 92.87% and Indels at 96.34%
- PPV of SNVs at 99.84% and Indels at 99.99%

# Reproducible variant calling



# ©2025. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. 04.2025.LAB. BC52025-0860-03MAR

# TSO500 assay specifications

Sample types	Plasma (EDTA, Streck or purified circulating-free nucleic acids)
Sample recommendations	<ul> <li>&gt; 3 mL plasma (minimum 2 mL plasma)</li> <li>Double-spun EDTA within 4 hr of collection OR</li> <li>Streck cfDNA BCT extends stability window to 6 days @ RT</li> </ul>
Input requirements	20-30 ng cfDNA (as quantified using fragment analysis)
Sequencing platform	NovaSeq 6000
Read depth	> 800 M PE Reads; 150 bp PE
Software analysis	Dragen
Regulatory	QC Report, VCFs (SNVs and Indels), CNVs, MSI and TMB scores BAMs can be made available upon request for additional fee

# IQVIA Laboratories global testing footprint





### Global consistency

Harmonized assay testing on 3 continents for consistent results.



# **Industry**

Leading in genomic testing since 2001.



### **Personalized** service

Custom turnaround times for delivery and analysis.



### **Massive data** delivery

1.2+ petabytes of genomic data globally in 2024.



### **Decades** of Expertise

Over 20 years in genomics testing.





Extensive experience working with the top 10 pharmaceutical

companies.



**IQVIA** Genomics has partnered with > 125 leading/top biotech companies.

# **CONTACT US**

Toll free: +1 855.277.9929

Direct: +1 919.998.7000

International: +44 (0) 1506 814000 IQVIA Laboratories: +1 919.405.2248

labs.iqvia.com

